ADVERTISEMENT

Suggestions

Today's Paper
Login
Thursday, May 21, 2026
Login

Johnson

A handout photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (COVID-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia (Courtesy: Reuters)

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

Bengaluru: A single dose of Johnson & Johnson’s experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on
Sep. 26, 2020
··

Follow

Newsletter